Shares of ImmuCell Corporation (ICCC) have fallen sharply since the release of third-quarter 2025 earnings. The stock has declined 22.7% since the announcement compared with a 3.9% drop of the S&P 500 over the same period. Over the past month, ImmuCell shares are down 23.1%, while the broader index has slipped a more modest 2%. This underperformance reflects heightened investor caution despite notable operational improvements reported by the company.Sales & Revenue PerformanceImmuCell’s third-quarter result ...